Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the “Cardiac Benefits” of Empagliflozin Independent of its Hypoglycemic Activity?

Cardiovascular Drugs and Therapy

Volumn 33, Issue 1, 2019, Pages 87-95

  Santos Gallego, Carlos G ^a   Garcia Ropero, Alvaro ^a   Mancini, Donna ^a   Pinney, Sean P ^a   Contreras, Johanna P ^a   Fergus, Icilma ^a   Abascal, Vivian ^a   Moreno, Pedro ^a   Atallah Lajam, Farah ^a   Tamler, Ronald ^b   Lala, Anu ^a   Sanz, Javier ^a   Fuster, Valentin ^a   Badimon, Juan Jose ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Mount Sinai University   (United States)

Author keywords

Cardiac magnetic resonance; Cardiac remodeling; Cardiopulmonary exercise test; Diabetes mellitus; Empagliflozin; Heart failure; SGLT2 inhibitors

Indexed keywords

EMPAGLIFLOZIN; PLACEBO; BENZHYDRYL DERIVATIVE; CARDIOVASCULAR AGENT; GLUCOSIDE;

ADULT; ANTIDIABETIC ACTIVITY; ARTICLE; CARDIOMYOPATHY; CARDIOPULMONARY EXERCISE TEST; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EPICARDIAL FAT; HEART FAILURE; HEART FUNCTION; HEART LEFT ATRIUM; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE MASS; HEART MUSCLE FIBROSIS; HEART MUSCLE METABOLISM; HEART RIGHT VENTRICLE FUNCTION; HEART RIGHT VENTRICLE VOLUME; HOSPITALIZATION; HUMAN; HYPOGLYCEMIA; KANSAS CARDIOMYOPATHY QUESTIONNAIRE; KETOACIDOSIS; MAJOR CLINICAL STUDY; PORCINE MODEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; SIX MINUTE WALK TEST; STUDY DESIGN; URINARY TRACT INFECTION; CONVALESCENCE; DRUG EFFECT; EXERCISE TOLERANCE; HEART LEFT VENTRICLE FUNCTION; NEW YORK; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TIME FACTOR; TREATMENT OUTCOME; WALK TEST;

BENZHYDRYL COMPOUNDS; CARDIOVASCULAR AGENTS; DOUBLE-BLIND METHOD; EXERCISE TOLERANCE; GLUCOSIDES; HEART FAILURE; HUMANS; MAGNETIC RESONANCE IMAGING; NEW YORK CITY; PROSPECTIVE STUDIES; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOVERY OF FUNCTION; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT; VENTRICULAR FUNCTION, RIGHT; WALK TEST;

EID: 85060656511     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-018-06850-0     Document Type: Article

References (30)

1. Low Wang CC, Hess CN, Hiatt WR, Goldfine AB. Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus—mechanisms, management, and clinical considerations. Circulation. 2016;133:2459–502.
2. Santos-Gallego CG, Picatoste B, Badimon JJ. Pathophysiology of acute coronary syndrome. Curr Atheroscler Rep. 2014;16:401.
3. Santos-Gallego CG, Rosenson RS. Role of HDL in those with diabetes. Curr Cardiol Rep. 2014;16:512.
4. Flores E, Santos-Gallego CG, Diaz-Mejia N, Badimon JJ. Do the SGLT-2 inhibitors offer more than hypoglycemic activity? Cardiovasc Drugs Ther. 2018;32:213–22.
5. Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, et al. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation. 2018;137:e67–e492.
6. Thomas MC. Type 2 diabetes and heart failure: challenges and solutions. Curr Cardiol Rev. 2016;12:249–55.
7. Lam CSP, Gamble GD, Ling LH, Sim D, Leong KTG, Yeo PSD, et al. Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study. Eur Heart J. 2018;39:1770–80.
8. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28.
9. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–34.
10. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–57.
11. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2018.
12. Ryan PB, Buse JB, Schuemie MJ, et al. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D). Diabetes Obes Metab. 2018;20:2585–97.
13. Marx N, McGuire DK. Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. Eur Heart J. 2016;37:3192–200.
14. Baartscheer A, Schumacher CA, Wust RC, et al. Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)/H(+) exchanger in rats and rabbits. Diabetologia. 2017;60:568–73.
15. Uthman L, Baartscheer A, Bleijlevens B, Schumacher CA, Fiolet JWT, Koeman A, et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na(+)/H(+) exchanger, lowering of cytosolic Na(+) and vasodilation. Diabetologia. 2018;61:722–6.
16. Theroux P, Chaitman BR, Danchin N, et al. Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. Main results of the GUARDIAN trial. Guard during ischemia against necrosis (GUARDIAN) investigators. Circulation. 2000;102:3032–8.
17. Santos-Gallego CG, Vahl TP, Goliasch G, Picatoste B, Arias T, Ishikawa K, et al. Sphingosine-1-phosphate receptor agonist fingolimod increases myocardial salvage and decreases adverse postinfarction left ventricular remodeling in a porcine model of ischemia/reperfusion. Circulation. 2016;133:954–66.
18. Santos-Gallego CG, Requena-Ibanez A, San Antonio R, et al. Empagliflozin Ameliorates Adverse LV Remodeling in a Non-Diabetic Model of Heart Failure Mediated via a Switch in Myocardial Metabolism That Enhances Energetics. J Am Coll Cardiol. 2019; in press.
19. Verma S, Garg A, Yan AT, et al. Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial? Diabetes Care. 2016;39:e212–13.
20. White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation. 1987;76:44–51.
21. Migrino RQ, Young JB, Ellis SG, White HD, Lundergan CF, Miller DP, et al. End-systolic volume index is a strong predictor of early and late mortality. The GUSTO-I Angiographic Investigators. Circulation. 1997;96:116–21.
22. Kramer DG, Trikalinos TA, Kent DM, Antonopoulos GV, Konstam MA, Udelson JE. Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. J Am Coll Cardiol. 2010;56:392–406.
23. Park JJ, Park JB, Park JH, Cho GY. Global longitudinal strain to predict mortality in patients with acute heart failure. J Am Coll Cardiol. 2018;71:1947–57.
24. Garcia-Ropero A, Badimon JJ, Santos-Gallego CG. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments. Expert Opin Drug Metab Toxicol. 2018;14:1287–302.
25. Malhotra R, Bakken K, D'Elia E, Lewis GD. Cardiopulmonary exercise testing in heart failure. JACC Heart Fail. 2016;4:607–16.
26. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an international forum on cardiac remodeling. J Am Coll Cardiol. 2000;35:569–82.
27. Verma A, Meris A, Skali H, Ghali JK, Arnold JM, Bourgoun M, et al. Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) echocardiographic study. JACC Cardiovasc Imaging. 2008;1:582–91.
28. Wong TC, Piehler K, Meier CG, Testa SM, Klock AM, Aneizi AA, et al. Association between extracellular matrix expansion quantified by cardiovascular magnetic resonance and short-term mortality. Circulation. 2012;126:1206–16.
29. Kim YG, Jeon JY, Han SJ, Kim DJ, Lee KW, Kim HJ. Sodium-glucose co-transporter-2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: a nationwide population-based cohort study. Diabetes Obes Metab. 2018.
30. Ferrannini E, Baldi S, Frascerra S, et al. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes. 2016;65:1190–5.